Valneva among the leaders of the SBF 120, 3% rebound

A rebound that remains below the stock's three moving averages

Valneva shares rise to €2.45, after €2.38 at the previous close. The stock ranks among the strongest gainers in the SBF 120, an index that is not moving at this stage of the session.

The stock gains 3.11% on the day, but it still loses 3.1% over one month and is down 39% over one year. Today's rebound therefore eases this monthly decline without fully recovering it.

On the technical side, the price remains below its three moving averages: 1.5% below the MM20 at €2.49, 8.2% below the MM50 and 16% below the MM200 at €2.92. The RSI at 45 remains neutral.

The €2.33 support level is about 5% below the price, and the €2.83 resistance is about 15% above. The stock had lost its €2.42 support on October 22, before recovering some ground.

Between the Lyme disease vaccine and the setback for Ixchiq, a shared case

The group's operations remain marked by two opposing matters. On October 7, the United Kingdom revoked the authorization of Ixchiq, its chikungunya vaccine, following a reassessment of the benefit-risk balance among travelers.

Conversely, the company indicated in mid-October that its Lyme disease vaccine candidate was among its main upcoming growth drivers. When publishing its H1 2026 results on August 13, Valneva had confirmed its outlook for the year, citing the persistent negative impact of the geopolitical context on travel.

The company had also mentioned expected regulatory decisions on the Lyme disease candidate within the following twelve months. Valneva, which is also listed on Nasdaq in the form of ADSs (1 ADS for 2 shares), conducts most of its trading in Paris.

In the sector, Sanofi rises 0.94% and gains 15.4% over one month. The next technical level to watch for Valneva is the MM20, at €2.49.